Compare Abbott Laboratories (ABT) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Ulta Beauty Inc — how do they compare? Abbott Laboratories trades at $110.14 (market cap $187.95B), while Ulta Beauty Inc trades at $533 (market cap $23.27B). The key difference: Abbott Laboratories is far larger — about 8.1× Ulta Beauty Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while Ulta Beauty Inc pays none. Which is the better fit depends on your goals.
| ABT | ULTA | |
|---|---|---|
Market Cap | $187.95B | $23.27B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $706.82 |
52-Week Low | $82.57 | $450.75 |
Enterprise Value | $214.96B | $25.35B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
ULTA Beauty trades at $548.66, down 2.92% on the day, with strong technical momentum indicated by bullish moving averages and key support at $542. Fundamentally, the company maintains robust profitability with 39.33% gross margins and 47.45% ROE, though recent earnings showed mixed results with a Q4 miss. Revenue growth has been consistent, reaching $11.3B in 2025, while analyst sentiment remains positive with 56.53% buy ratings.
The outlook for ULTA remains favorable with a consensus price target of $618.29 offering 12.7% upside potential. Key opportunities include omnichannel expansion and digital growth initiatives, while risks involve margin pressure from rising costs and competitive retail landscape. Institutional ownership trends show continued confidence with recent position increases by major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
